Methods for identifying and treating invasive/metastatic breast cancers
Cancer invasion is a hallmark of metastasis. The mesenchymal mode of cancer cell invasion is mediated by elongated membrane protrusions driven by the assembly of branched F-actin networks. Described herein are compositions and methods for assessing and treating a subject having metastatic cancer or at risk of developing metastatic cancer, e.g., metastatic breast cancer, through the determination of Lamellipodin protein or gene expression levels in the subject.
1. A method for diagnosing and treating a metastatic breast cancer in a subject, the method comprising
obtaining a breast tissue sample from a subject;
detecting the amount or level of Lamellipodin (Lpd) protein in the sample with an anti-Lpd antibody or Lpd-binding polypeptide;
comparing the amount or level of Lpd protein from the sample to a control, wherein an increased amount of Lpd protein is indicative of a metastatic breast cancer or a breast cancer at risk of becoming metastatic;
diagnosing the subject with metastatic breast cancer or as being at risk of developing metastatic breast cancer when the amount of Lpd protein is enhanced as compared to the control; and
treating the subject having metastatic breast cancer or at risk of developing metastatic breast cancer with an effective amount of an anti-cancer therapeutic that includes at least one of: an Abl tyrosine kinase inhibitor; a Src tyrosine kinase inhibitor; a siRNA, shRNA, or a combination thereof that targets a Lpd encoding nucleic acid; or a combination thereof,
wherein the effective amount of an anti-cancer therapeutic is effective at treating, reducing or ameliorating a symptom of metastatic breast cancer, the progression of metastatic breast cancer, or both.
2. The method of claim 1 , wherein the amount of Lpd protein is determined by detecting the amount of anti-Lpd antibody bound by surface plasmon resonance.
3. The method of claim 2 , wherein, the antibody binds to an epitope encoded by the amino acid sequence of SEQ ID NO:2.
4. A method of treating a metastatic breast cancer in a patient, the method comprising:
administering an effective amount of an anti-cancer therapeutic to a patient having a breast tumor overexpressing Lpd protein,
wherein:
the anti-cancer therapeutic includes at least one of: an Abl tyrosine kinase inhibitor; a Src tyrosine kinase inhibitor; a siRNA, shRNA, or a combination thereof that targets a Lpd encoding nucleic acid; or a combination thereof; and
the effective amount of an anti-cancer therapeutic is effective at treating, reducing or ameliorating a symptom of metastatic breast cancer, the progression of metastatic breast cancer, or both.
5. The method of claim 1 , wherein the breast tissue sample is a breast cancer tissue.
6. The method of claim 1 , wherein the breast tissue sample is a metastatic breast cancer tissue.
7. A method for diagnosing and treating a metastatic breast cancer in a subject, the method comprising
obtaining a breast tissue sample from a subject;
detecting the amount or level of Lamellipodin (Lpd) gene expression in the sample with a labelled nucleic acid probe that is complementary to an Lpd encoding nucleic acid;
comparing the amount or level of Lpd gene expression from the sample to a control, wherein an increased amount of Lpd gene expression is indicative of a metastatic breast cancer or a breast cancer at risk of becoming metastatic;
diagnosing the subject with metastatic breast cancer or as being at risk of developing metastatic breast cancer when the amount of Lpd gene expression is enhanced as compared to the control; and
treating the subject having metastatic breast cancer or at risk of developing metastatic breast cancer with an effective amount of an anti-cancer therapeutic that includes at least one of: an Abl tyrosine kinase inhibitor; a Src tyrosine kinase inhibitor; a siRNA, shRNA, or a combination thereof that targets a Lpd encoding nucleic acid; or a combination thereof,
wherein the effective amount of an anti-cancer therapeutic is effective at treating, reducing or ameliorating a symptom of metastatic breast cancer, the progression of metastatic breast cancer, or both.
8. The method of claim 7 , wherein the breast tissue sample is a breast cancer tissue.
9. The method of claim 7 , wherein the breast tissue sample is a metastatic breast cancer tissue.
10. The method of claim 4 , wherein the breast tumor is a metastatic breast cancer tissue.
11. The method of claim 1 , wherein the therapeutic is selected from Imatinib, Nilotinib, or a combinations thereof.